Compare TBI & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBI | MBOT |
|---|---|---|
| Founded | 1985 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.9M | 145.7M |
| IPO Year | 1995 | 2000 |
| Metric | TBI | MBOT |
|---|---|---|
| Price | $4.24 | $2.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $7.50 |
| AVG Volume (30 Days) | 252.2K | ★ 2.2M |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.39 | 30.48 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $116,887.00 |
| Revenue This Year | $6.25 | N/A |
| Revenue Next Year | $3.90 | $4,186.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.44 | $1.34 |
| 52 Week High | $7.78 | $4.62 |
| Indicator | TBI | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 44.41 | 56.58 |
| Support Level | $3.44 | $2.34 |
| Resistance Level | $6.28 | $2.68 |
| Average True Range (ATR) | 0.27 | 0.17 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 60.80 | 55.00 |
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.